Bavarian Nordic A/S
17.12.2025 08:30:00 CET | Globenewswire | Press release
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair.
Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and commercial development through to launch execution. She is formerly President at Cardinal Health, where she led the Specialty Solutions Businesses. Prior to Cardinal Health, Ms. Hunter held senior leadership positions at UCB, Boehringer Ingelheim, IQVIA and Centocor, a J&J company. She also led women’s health and oncology business at Wyeth (today part of Pfizer) in the U.S. and women’s health at Novo Nordisk in Denmark. Ms. Hunter holds a BA from the University of Michigan and an MBA from the University of Chicago.
In addition to the role as Vice Chair, Ms. Hunter’s duties on the Board include memberships of the Nomination and Compensation Committee and the Science and Technology Committee.
Her external duties include board memberships with Vicore Pharma Holding AB, IO Biotech, Inc. and Sutro BioPharma Inc.
The Board continues its search for a couple of candidates with relevant competencies to be nominated for election at the annual general meeting in April 2026, while at the same time securing continuity.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.
Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Chery Group2.4.2026 15:51:47 CEST | Press release
Behind the World’s Fastest Growth: OMODA & JAECOO Unveil Third-Anniversary Achievements at the Beijing Auto Show
ProMach2.4.2026 15:00:00 CEST | Press release
ProMach Acquires Evolution BPS, a Leading Equipment and Services Provider for the UK Food and Beverage Sector
ZenaTech Inc.2.4.2026 14:30:00 CEST | Press release
ZenaTech Initiates New Operations in Ukraine to Accelerate Production of Counter-UAS Interceptor Systems
NANO-X IMAGING LTD2.4.2026 14:11:00 CEST | Press release
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
Freshworks Inc2.4.2026 14:00:00 CEST | Press release
Freshworks Expands IT Asset Management Capabilities by Adding Continuous Infrastructure Discovery and Dependency Mapping to Freshservice
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom